141 related articles for article (PubMed ID: 24885059)
21. Regulation and Function of the PD-L1 Checkpoint.
Sun C; Mezzadra R; Schumacher TN
Immunity; 2018 Mar; 48(3):434-452. PubMed ID: 29562194
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Coelho MA; de Carné Trécesson S; Rana S; Zecchin D; Moore C; Molina-Arcas M; East P; Spencer-Dene B; Nye E; Barnouin K; Snijders AP; Lai WS; Blackshear PJ; Downward J
Immunity; 2017 Dec; 47(6):1083-1099.e6. PubMed ID: 29246442
[TBL] [Abstract][Full Text] [Related]
23. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
24. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
Li CW; Lim SO; Xia W; Lee HH; Chan LC; Kuo CW; Khoo KH; Chang SS; Cha JH; Kim T; Hsu JL; Wu Y; Hsu JM; Yamaguchi H; Ding Q; Wang Y; Yao J; Lee CC; Wu HJ; Sahin AA; Allison JP; Yu D; Hortobagyi GN; Hung MC
Nat Commun; 2016 Aug; 7():12632. PubMed ID: 27572267
[TBL] [Abstract][Full Text] [Related]
25. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Kataoka K; Shiraishi Y; Takeda Y; Sakata S; Matsumoto M; Nagano S; Maeda T; Nagata Y; Kitanaka A; Mizuno S; Tanaka H; Chiba K; Ito S; Watatani Y; Kakiuchi N; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Itonaga H; Imaizumi Y; Totoki Y; Munakata W; Nakamura H; Hama N; Shide K; Kubuki Y; Hidaka T; Kameda T; Masuda K; Minato N; Kashiwase K; Izutsu K; Takaori-Kondo A; Miyazaki Y; Takahashi S; Shibata T; Kawamoto H; Akatsuka Y; Shimoda K; Takeuchi K; Seya T; Miyano S; Ogawa S
Nature; 2016 Jun; 534(7607):402-6. PubMed ID: 27281199
[TBL] [Abstract][Full Text] [Related]
26. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
Liao L; Xu H; Zhao Y; Zheng X
Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
[TBL] [Abstract][Full Text] [Related]
27. Interferon-gamma and tumor necrosis factor-alpha synergistically enhance the immunosuppressive capacity of human umbilical-cord-derived mesenchymal stem cells by increasing PD-L1 expression.
Chen Z; Yao MW; Shen ZL; Li SD; Xing W; Guo W; Li Z; Wu XF; Ao LQ; Lu WY; Lian QZ; Xu X; Ao X
World J Stem Cells; 2023 Aug; 15(8):787-806. PubMed ID: 37700823
[TBL] [Abstract][Full Text] [Related]
28. Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies.
Atajanova T; Rahman MM; Konieczkowski DJ; Morris ZS
Cancer Immunol Immunother; 2023 Nov; 72(11):3445-3452. PubMed ID: 37658906
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for Recurrent Glioma-From Bench to Bedside.
Pu Y; Zhou G; Zhao K; Chen Y; Shen S
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444531
[TBL] [Abstract][Full Text] [Related]
30. Regulation of PD-L1 Trafficking from Synthesis to Degradation.
Lemma EY; Letian A; Altorki NK; McGraw TE
Cancer Immunol Res; 2023 Jul; 11(7):866-874. PubMed ID: 37290119
[TBL] [Abstract][Full Text] [Related]
31. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
Cruz Cruz J; Allison KC; Page LS; Jenkins AJ; Wang X; Earp HS; Frye SV; Graham DK; Verneris MR; Lee-Sherick AB
Front Immunol; 2023; 14():1146721. PubMed ID: 36960055
[TBL] [Abstract][Full Text] [Related]
32. Emerging phagocytosis checkpoints in cancer immunotherapy.
Liu Y; Wang Y; Yang Y; Weng L; Wu Q; Zhang J; Zhao P; Fang L; Shi Y; Wang P
Signal Transduct Target Ther; 2023 Mar; 8(1):104. PubMed ID: 36882399
[TBL] [Abstract][Full Text] [Related]
33. Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies.
Meliante PG; Barbato C; Zoccali F; Ralli M; Greco A; de Vincentiis M; Colizza A; Petrella C; Ferraguti G; Minni A; Fiore M
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499710
[TBL] [Abstract][Full Text] [Related]
34. Tumor immune checkpoints and their associated inhibitors.
Gao Z; Ling X; Shi C; Wang Y; Lin A
J Zhejiang Univ Sci B; 2022 Oct; 23(10):823-843. PubMed ID: 36226537
[TBL] [Abstract][Full Text] [Related]
35. Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer.
Wu Y; Yu S; Qiao H
Front Pharmacol; 2022; 13():990445. PubMed ID: 36120342
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis.
Mamat Yusof MN; Chew KT; Kampan N; Abd Aziz NH; Md Zin RR; Tan GC; Shafiee MN
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010904
[TBL] [Abstract][Full Text] [Related]
37. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Denize T; Hou Y; Pignon JC; Walton E; West DJ; Freeman GJ; Braun DA; Wu CJ; Gupta S; Motzer RJ; Atkins MB; McDermott D; Choueiri TK; Shukla SA; Signoretti S
Clin Cancer Res; 2022 Sep; 28(18):4045-4055. PubMed ID: 35802667
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis.
Ohwada S; Ishigami K; Akutsu N; Nakase H
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740355
[TBL] [Abstract][Full Text] [Related]
39. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation.
Fan Z; Wu C; Chen M; Jiang Y; Wu Y; Mao R; Fan Y
Acta Pharm Sin B; 2022 Mar; 12(3):1041-1053. PubMed ID: 35530130
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.
Yamaguchi H; Hsu JM; Yang WH; Hung MC
Nat Rev Clin Oncol; 2022 May; 19(5):287-305. PubMed ID: 35132224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
